Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a live webcast of its fiscal 2011 first-quarter conference call on Wednesday, November 3, 2010, at 3:45 p.m. CT (4:45 p.m. ET). David L. Martin, president and chief executive officer, and Laurence L. Betterley, chief financial officer, will discuss the company’s results for its fiscal first quarter ended September 30, 2010, and its financial outlook. The company will issue a post-market earnings release on November 3.

To access the live webcast, go to the investor information section of the company’s website, www.csi360.com, on the day of the conference call and click on the webcast icon. A webcast replay will be available beginning at 7 p.m. CT the same day.

To participate in the conference call, dial (888) 713-4213 and enter 71223045. Please dial in at least 10 minutes prior to the call. To pre-register for the call, log on to the following website: https://cossprereg.btci.com/prereg/key.process?key=P86RXC3YU. When joining the call, pre-registered participants can enter their PIN code, and other participants can press *0 to go directly to the operator, or wait on the line for operator assistance.

If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial (888) 286-8010 and enter access number 84340989. The audio replay will be available beginning at 8 p.m. CT on Wednesday, November 3, 2010, through 6 p.m. CT on Friday, November 5, 2010.

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing interventional treatment systems for vascular disease. The company’s Diamondback 360 ® and Diamondback Predator 360™ PAD Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. As many as 12 million Americans suffer from peripheral arterial disease (PAD), which is caused by the accumulation of plaque in peripheral arteries (commonly the pelvis or leg) reducing blood flow. Symptoms include leg pain when walking or at rest, and can lead to tissue loss and eventually limb amputation. In August 2007, the U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° as a therapy for PAD, and CSI commenced a U.S. product launch in September 2007. Since then, more than 30,000 procedures have been performed using the Diamondback 360° in leading institutions across the United States. For more information visit the company’s Web site at www.csi360.com.

Copyright Business Wire 2010